TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

Rhea-AI Summary

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics (Nasdaq: TCRR) announced participation in the 34th Annual Piper Sandler Healthcare Conference on November 29 at 2:00 PM E.T. The event will feature a fireside chat with management, and a live webcast can be accessed on the Company’s Investors page. An archived replay will be available for 30 days following the event. TCR2 specializes in developing novel T cell therapies for solid tumors, utilizing its TRuC platform to target and eliminate cancer cells.

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.

A live webcast of the presentation will be available on the Investors page of the Company’s website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR2 Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The Company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

When will TCR2 Therapeutics participate in the Piper Sandler Healthcare Conference?

TCR2 Therapeutics will participate in the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 2:00 PM E.T.

Where can I watch the TCR2 Therapeutics conference presentation?

The presentation will be available via a live webcast on the Investors page of TCR2 Therapeutics' website.

How long will the TCR2 conference presentation be available for replay?

An archived replay of the TCR2 Therapeutics presentation will be available for at least 30 days following the event.

What is TCR2 Therapeutics focusing on in their research?

TCR2 Therapeutics is focused on developing novel T cell therapies for patients with solid tumors using their TRuC platform.

What is the ticker symbol for TCR2 Therapeutics?

The ticker symbol for TCR2 Therapeutics is TCRR.